| Official Webiste | |
| Event | 2022 ICCB & APOCB |
| Time | November 7- 11, 2022 |
| Location |
H.S.S. Building, Academia Sinica, Taipei Taiwan
|
| Time and Venue for the Tang Prize Lecture |
November 11, 2022 |
| Speaker |
Dr. Tadamitsu Kishimoto |
| Title |
Interleukin 6: from Arthritis to COVID-19 |
| Lecture Outline | Interleukin-6 (IL-6) possesses the diverse biological activity that contributes to the maintenance of homeostasis. Emergent cases of infection or tissue injury induce rapidly production of IL-6 and activates host defense through the augmentation of acute phase proteins and immune responses. However, excessive IL-6 production and uncontrolled IL-6 receptor signaling have critical roles in disease pathogenesis. Over the years, therapeutic agents targeting IL-6 signaling, such as tocilizumab, a humanized anti-IL-6 receptor antibody, have shown remarkable efficacy for rheumatoid arthritis, Castleman`s disease, and juvenile idiopathic arthritis, and applicable diseases are continuously being reported. Emerging evidence has demonstrated the beneficial efficacy of tocilizumab for several types of acute inflammatory diseases including chimeric antigen receptor T-cell therapy-induced cytokine storms and coronavirus diseases 2019 (COVID-19). Here, we refocus attention on the biology of IL-6 and summarize the distinct pathological roles of IL-6 signaling in several acute and chronic inflammatory diseases. |